Back to results
US 2022/0008513 A1Published application
Combined treatment of primary central nervous system lymphoma
AssigneeFondazione Centro San Raffaele
InventorsAngelo CORTI, Andrés José Maria FERRERI
Life of this patent
Estimating the term…
Abstract
The present invention refers to the combination of an R-CHOP therapy with an administration of NGR-hTNF or an analog thereof for the treatment of primary central nervous system lymphoma, preferably relapsed/refractory primary central nervous system lymphoma.
Claims7
A method for the treatment of primary central nervous system lymphoma in a subject, comprising administering a combination of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and NGR-hTNF or an analog thereof
- wherein the combination comprises at least one course of R-CHOP preceded by an administration of NGR-hTNF or an analog thereof.
Dependencies are inferred from the claim text.